Seres Therapeutics - MCRB Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Seres Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MCRB shares.
View MCRB analyst ratings or view top-rated stocks.

3 analysts have issued 12 month target prices for Seres Therapeutics' shares. Their MCRB share price forecasts range from $7.00 to $25.00. On average, they predict the company's share price to reach $14.67 in the next year. This suggests a possible upside of 174.7% from the stock's current price.
View analysts price targets for MCRB or view top-rated stocks among Wall Street analysts.

Seres Therapeutics' stock was trading at $8.33 at the beginning of 2022. Since then, MCRB stock has decreased by 35.9% and is now trading at $5.34.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our MCRB earnings forecast.

Seres Therapeutics, Inc. (NASDAQ:MCRB) issued its quarterly earnings results on Wednesday, November, 10th. The biotechnology company reported $0.72 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.47) by $1.19. The biotechnology company earned $126.73 million during the quarter, compared to analyst estimates of $7.12 million. Seres Therapeutics had a negative trailing twelve-month return on equity of 100.32% and a negative net margin of 75.48%. During the same period in the prior year, the firm posted ($0.36) earnings per share.

Based on aggregate information from My MarketBeat watchlists, some companies that other Seres Therapeutics investors own include OPKO Health (OPK), TherapeuticsMD (TXMD), Juno Therapeutics (JUNO), NVIDIA (NVDA), Walt Disney (DIS), Alibaba Group (BABA), Novavax (NVAX), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX) and Gilead Sciences (GILD).

(MCRB) raised $101 million in an initial public offering (IPO) on Friday, June 26th 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Leerink Partners and Canaccord Genuity were co-managers.

Seres Therapeutics trades on the NASDAQ under the ticker symbol "MCRB."

Seres Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include FMR LLC (14.99%), JPMorgan Chase & Co. (0.85%), Sumitomo Mitsui Trust Holdings Inc. (0.76%), Nikko Asset Management Americas Inc. (0.76%), Silverarc Capital Management LLC (0.38%) and Sit Investment Associates Inc. (0.22%). Insiders that own company stock include Health Ltp Fund Ge Nutritional and Marcus Chapman.
View institutional ownership trends.

Shares of MCRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MCRB stock can currently be purchased for approximately $5.34.

Seres Therapeutics (NASDAQ:MCRB) has a market capitalization of $662.53 million and generates $144.93 million in revenue each year. The biotechnology company earns $-65,580,000.00 in net income (profit) each year or ($1.14) on an earnings per share basis.

The company employs 333 workers across the globe.

Seres Therapeutics' mailing address is 200 SIDNEY STREET - 4TH FLOOR, CAMBRIDGE MA, 02139. The official website for the company is www.serestherapeutics.com. The biotechnology company can be reached via phone at (617) 945-9626 or via email at ctanzi@serestherapeutics.com.